China Probe Reveals Widespread Drug Data Violations At Major Study Centers
This article was originally published in SRA
Executive Summary
Severe adverse events left unreported, critical data gone missing, subject drugs substituted to pass bioequivalent testing - these are just some of the wrongdoings disclosed by the China Food and Drug Administration in a rare report on regulatory transgressions during drug trials conducted in the country.
You may also be interested in...
2016 Review: Rapid Change Defines China Regulatory Environment
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
China Clarifies Position on Forged Trial Data As 30 Applications Are Rejected
As more new drug applications get rejected under the China Food and Drug Administration’s drive to stamp out trial data forgery, the regulator has issued draft guidance to clarify its position on data integrity breaches.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.